These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31362591)

  • 1. Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT.
    Shahu A; Herrin J; Dhruva SS; Desai NR; Davis BR; Krumholz HM; Spatz ES
    J Am Heart Assoc; 2019 Aug; 8(15):e012277. PubMed ID: 31362591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Blood Pressure Measurements With Peripheral Artery Disease Events.
    Itoga NK; Tawfik DS; Lee CK; Maruyama S; Leeper NJ; Chang TI
    Circulation; 2018 Oct; 138(17):1805-1814. PubMed ID: 29930023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
    Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS;
    JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
    Piller LB; Baraniuk S; Simpson LM; Cushman WC; Massie BM; Einhorn PT; Oparil S; Ford CE; Graumlich JF; Dart RA; Parish DC; Retta TM; Cuyjet AB; Jafri SZ; Furberg CD; Saklayen MG; Thadani U; Probstfield JL; Davis BR;
    Circulation; 2011 Oct; 124(17):1811-8. PubMed ID: 21969009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Cushman WC; Davis BR; Pressel SL; Cutler JA; Einhorn PT; Ford CE; Oparil S; Probstfield JL; Whelton PK; Wright JT; Alderman MH; Basile JN; Black HR; Grimm RH; Hamilton BP; Haywood LJ; Ong ST; Piller LB; Simpson LM; Stanford C; Weiss RJ;
    J Clin Hypertens (Greenwich); 2012 Jan; 14(1):20-31. PubMed ID: 22235820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dhruva SS; Huang C; Spatz ES; Coppi AC; Warner F; Li SX; Lin H; Xu X; Furberg CD; Davis BR; Pressel SL; Coifman RR; Krumholz HM
    Hypertension; 2017 Jul; 70(1):94-102. PubMed ID: 28559399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
    Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
    J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.
    Dewland TA; Soliman EZ; Davis BR; Magnani JW; Yamal JM; Piller LB; Haywood LJ; Alonso A; Albert CM; Marcus GM;
    JAMA Intern Med; 2016 Aug; 176(8):1085-92. PubMed ID: 27367818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in Mortality and Cardiovascular Events by Income and Blood Pressure Levels Among Patients With Hypertension in South Korea.
    Shin JH; Jung MH; Kwon CH; Lee CJ; Kim DH; Kim HL; Kim W; Kang SH; Lee JH; Kim HM; Cho IJ; Cho I; Lee JH; Kang DR; Lee HY; Chung WJ; Ihm SH; Kim KI; Cho EJ; Sohn IS; Kim HC; Park S; Shin J; Kim JH; Ryu SK; Kang SM; Pyun WB; Cho MC; Sung KC
    J Am Heart Assoc; 2021 Apr; 10(7):e018446. PubMed ID: 33719521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study.
    Echouffo-Tcheugui JB; Zhao S; Brock G; Matsouaka RA; Kline D; Joseph JJ
    Diabetes Care; 2019 Mar; 42(3):486-493. PubMed ID: 30659073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
    Juraschek SP; Simpson LM; Davis BR; Beach JL; Ishak A; Mukamal KJ
    Hypertension; 2019 Oct; 74(4):1033-1040. PubMed ID: 31476905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.
    Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT;
    J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension.
    Furberg CD; Psaty BM; Pahor M; Alderman MH
    Ann Intern Med; 2001 Dec; 135(12):1074-8. PubMed ID: 11747386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Whelton PK; Williamson JD; Louis GT; Davis BR; Cutler JA
    Clin Exp Hypertens; 1996; 18(3-4):569-79. PubMed ID: 8743044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
    Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
    JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.